<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">35563635</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>18</Day>
      </DateRevised>
      <Article PubModel="Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1422-0067</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>23</Volume>
            <Issue>9</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>08</Day>
            </PubDate>
          </JournalIssue>
          <Title>International journal of molecular sciences</Title>
          <ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Multiomic Profiling Identified EGF Receptor Signaling as a Potential Inhibitor of Type I Interferon Response in Models of Oncolytic Therapy by Vesicular Stomatitis Virus.</ArticleTitle>
        <ELocationID EIdType="pii" ValidYN="Y">5244</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms23095244</ELocationID>
        <Abstract>
          <AbstractText>Cancer cell lines responded differentially to type I interferon treatment in models of oncolytic therapy using vesicular stomatitis virus (VSV). Two opposite cases were considered in this study, glioblastoma DBTRG-05MG and osteosarcoma HOS cell lines exhibiting resistance and sensitivity to VSV after the treatment, respectively. Type I interferon responses were compared for these cell lines by integrative analysis of the transcriptome, proteome, and RNA editome to identify molecular factors determining differential effects observed. Adenosine-to-inosine RNA editing was equally induced in both cell lines. However, transcriptome analysis showed that the number of differentially expressed genes was much higher in DBTRG-05MG with a specific enrichment in inflammatory proteins. Further, it was found that two genes, EGFR and HER2, were overexpressed in HOS cells compared with DBTRG-05MG, supporting recent reports that EGF receptor signaling attenuates interferon responses via HER2 co-receptor activity. Accordingly, combined treatment of cells with EGF receptor inhibitors such as gefitinib and type I interferon increases the resistance of sensitive cell lines to VSV. Moreover, sensitive cell lines had increased levels of HER2 protein compared with non-sensitive DBTRG-05MG. Presumably, the level of this protein expression in tumor cells might be a predictive biomarker of their resistance to oncolytic viral therapy.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Nikitina</LastName>
            <ForeName>Anastasia S</ForeName>
            <Initials>AS</Initials>
            <Identifier Source="ORCID">0000-0002-4321-3693</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lipatova</LastName>
            <ForeName>Anastasia V</ForeName>
            <Initials>AV</Initials>
            <AffiliationInfo>
              <Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Goncharov</LastName>
            <ForeName>Anton O</ForeName>
            <Initials>AO</Initials>
            <Identifier Source="ORCID">0000-0001-5538-5655</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pirogov Russian National Research Medical University, 117997 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kliuchnikova</LastName>
            <ForeName>Anna A</ForeName>
            <Initials>AA</Initials>
            <Identifier Source="ORCID">0000-0001-9230-1238</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pirogov Russian National Research Medical University, 117997 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Pyatnitskiy</LastName>
            <ForeName>Mikhail A</ForeName>
            <Initials>MA</Initials>
            <Identifier Source="ORCID">0000-0002-4803-8150</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Institute of Biomedical Chemistry, 119121 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Kuznetsova</LastName>
            <ForeName>Ksenia G</ForeName>
            <Initials>KG</Initials>
            <Identifier Source="ORCID">0000-0001-7447-4047</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Hamad</LastName>
            <ForeName>Azzam</ForeName>
            <Initials>A</Initials>
            <Identifier Source="ORCID">0000-0002-7481-1450</Identifier>
            <AffiliationInfo>
              <Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Moscow Institute of Physics and Technology, 141700 Dolgoprudniy, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Vorobyev</LastName>
            <ForeName>Pavel O</ForeName>
            <Initials>PO</Initials>
            <AffiliationInfo>
              <Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Moscow Institute of Physics and Technology, 141700 Dolgoprudniy, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Alekseeva</LastName>
            <ForeName>Olga N</ForeName>
            <Initials>ON</Initials>
            <Identifier Source="ORCID">0000-0003-3910-466X</Identifier>
            <AffiliationInfo>
              <Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Mahmoud</LastName>
            <ForeName>Marah</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Moscow Institute of Physics and Technology, 141700 Dolgoprudniy, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Shakiba</LastName>
            <ForeName>Yasmin</ForeName>
            <Initials>Y</Initials>
            <Identifier Source="ORCID">0000-0002-6929-2414</Identifier>
            <AffiliationInfo>
              <Affiliation>Moscow Institute of Physics and Technology, 141700 Dolgoprudniy, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Anufrieva</LastName>
            <ForeName>Ksenia S</ForeName>
            <Initials>KS</Initials>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Arapidi</LastName>
            <ForeName>Georgy P</ForeName>
            <Initials>GP</Initials>
            <Identifier Source="ORCID">0000-0003-2323-1859</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ivanov</LastName>
            <ForeName>Mark V</ForeName>
            <Initials>MV</Initials>
            <AffiliationInfo>
              <Affiliation>V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tarasova</LastName>
            <ForeName>Irina A</ForeName>
            <Initials>IA</Initials>
            <AffiliationInfo>
              <Affiliation>V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Gorshkov</LastName>
            <ForeName>Mikhail V</ForeName>
            <Initials>MV</Initials>
            <Identifier Source="ORCID">0000-0001-9572-3452</Identifier>
            <AffiliationInfo>
              <Affiliation>V.L. Talrose Institute for Energy Problems of Chemical Physics, N.N. Semenov Federal Research Center for Chemical Physics, Russian Academy of Sciences, 119334 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Chumakov</LastName>
            <ForeName>Peter M</ForeName>
            <Initials>PM</Initials>
            <AffiliationInfo>
              <Affiliation>Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Moshkovskii</LastName>
            <ForeName>Sergei A</ForeName>
            <Initials>SA</Initials>
            <Identifier Source="ORCID">0000-0003-1697-9201</Identifier>
            <AffiliationInfo>
              <Affiliation>Federal Research and Clinical Center of Physical-Chemical Medicine, 119435 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Pirogov Russian National Research Medical University, 117997 Moscow, Russia.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>08</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Int J Mol Sci</MedlineTA>
        <NlmUniqueID>101092791</NlmUniqueID>
        <ISSNLinking>1422-0067</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D007370">Interferon Type I</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.1</RegistryNumber>
          <NameOfSubstance UI="D066246">ErbB Receptors</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D066246" MajorTopicYN="N">ErbB Receptors</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007370" MajorTopicYN="Y">Interferon Type I</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054243" MajorTopicYN="Y">Vesicular Stomatitis</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D014721" MajorTopicYN="N">Vesicular stomatitis Indiana virus</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D018116" MajorTopicYN="N">Vesiculovirus</DescriptorName>
          <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">epidermal growth factor receptor</Keyword>
        <Keyword MajorTopicYN="N">gefitinib</Keyword>
        <Keyword MajorTopicYN="N">glioblastoma</Keyword>
        <Keyword MajorTopicYN="N">human epidermal growth factor receptor 2</Keyword>
        <Keyword MajorTopicYN="N">oncolytic virus</Keyword>
        <Keyword MajorTopicYN="N">osteosarcoma</Keyword>
        <Keyword MajorTopicYN="N">type I interferon</Keyword>
        <Keyword MajorTopicYN="N">vesicular stomatitis virus</Keyword>
      </KeywordList>
      <CoiStatement>The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>30</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>6</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>1</Hour>
          <Minute>7</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35563635</ArticleId>
        <ArticleId IdType="pmc">PMC9102229</ArticleId>
        <ArticleId IdType="doi">10.3390/ijms23095244</ArticleId>
        <ArticleId IdType="pii">ijms23095244</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Spiesschaert B., Angerer K., Park J., Wollmann G. Combining Oncolytic Viruses, and Small Molecule Therapeutics: Mutual Benefits. Cancers. 2021;13:3386.  doi: 10.3390/cancers13143386.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13143386</ArticleId>
            <ArticleId IdType="pmc">PMC8306439</ArticleId>
            <ArticleId IdType="pubmed">34298601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Leung E.Y.L., McNeish I.A. Strategies to Optimise Oncolytic Viral Therapies: The Role of Natural Killer Cells. Viruses. 2021;13:1450.  doi: 10.3390/v13081450.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/v13081450</ArticleId>
            <ArticleId IdType="pmc">PMC8402671</ArticleId>
            <ArticleId IdType="pubmed">34452316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shi T., Song X., Wang Y., Liu F., Wei J. Combining Oncolytic Viruses with Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment. Front. Immunol. 2020;11:683. doi: 10.3389/fimmu.2020.00683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3389/fimmu.2020.00683</ArticleId>
            <ArticleId IdType="pmc">PMC7198760</ArticleId>
            <ArticleId IdType="pubmed">32411132</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lan Q., Xia S., Wang Q., Xu W., Huang H., Jiang S., Lu L. Development of oncolytic virotherapy: From genetic modification to combination therapy. Front. Med. 2020;14:160–184. doi: 10.1007/s11684-020-0750-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s11684-020-0750-4</ArticleId>
            <ArticleId IdType="pmc">PMC7101593</ArticleId>
            <ArticleId IdType="pubmed">32146606</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Crupi M.J.F., Bell J.C., Singaravelu R. Concise Review: Targeting Cancer Stem Cells and Their Supporting Niche Using Oncolytic Viruses. Stem Cells. 2019;37:716–723. doi: 10.1002/stem.3004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/stem.3004</ArticleId>
            <ArticleId IdType="pubmed">30875126</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ferrucci P.F., Pala L., Conforti F., Cocorocchio E. Talimogene Laherparepvec (T-VEC): An Intralesional Cancer Immunotherapy for Advanced Melanoma. Cancers. 2021;13:1383.  doi: 10.3390/cancers13061383.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3390/cancers13061383</ArticleId>
            <ArticleId IdType="pmc">PMC8003308</ArticleId>
            <ArticleId IdType="pubmed">33803762</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hastie E., Grdzelishvili V.Z. Vesicular stomatitis virus as a flexible platform for oncolytic virotherapy against cancer. J. Gen. Virol. 2012;93:2529–2545. doi: 10.1099/vir.0.046672-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1099/vir.0.046672-0</ArticleId>
            <ArticleId IdType="pmc">PMC4091291</ArticleId>
            <ArticleId IdType="pubmed">23052398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roy D.G., Geoffroy K., Marguerie M., Khan S.T., Martin N.T., Kmiecik J., Bobbala D., Aitken A.S., de Souza C.T., Stephenson K.B., et al.  Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination. Nat. Commun. 2021;12:2626. doi: 10.1038/s41467-021-22929-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41467-021-22929-z</ArticleId>
            <ArticleId IdType="pmc">PMC8113265</ArticleId>
            <ArticleId IdType="pubmed">33976179</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stojdl D.F., Lichty B., Knowles S., Marius R., Atkins H., Sonenberg N., Bell J.C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 2000;6:821–825. doi: 10.1038/77558.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/77558</ArticleId>
            <ArticleId IdType="pubmed">10888934</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tarasova I.A., Tereshkova A.V., Lobas A.A., Solovyeva E.M., Sidorenko A.S., Gorshkov V., Kjeldsen F., Bubis J.A., Ivanov M.V., Ilina I.Y., et al.  Comparative proteomics as a tool for identifying specific alterations within interferon response pathways in human glioblastoma multiforme cells. Oncotarget. 2018;9:1785–1802. doi: 10.18632/oncotarget.22751.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.18632/oncotarget.22751</ArticleId>
            <ArticleId IdType="pmc">PMC5788599</ArticleId>
            <ArticleId IdType="pubmed">29416731</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Grünvogel O., Esser-Nobis K., Windisch M.P., Frese M., Trippler M., Bartenschlager R., Lohmann V., Binder M. Type I and type II interferon responses in two human liver cell lines (Huh-7 and HuH6) Genom. Data. 2016;7:166–170. doi: 10.1016/j.gdata.2015.12.017.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.gdata.2015.12.017</ArticleId>
            <ArticleId IdType="pmc">PMC4778650</ArticleId>
            <ArticleId IdType="pubmed">26981398</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadjadj J., Yatim N., Barnabei L., Corneau A., Boussier J., Smith N., Péré H., Charbit B., Bondet V., Chenevier-Gobeaux C., et al.  Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369:718–724. doi: 10.1126/science.abc6027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1126/science.abc6027</ArticleId>
            <ArticleId IdType="pmc">PMC7402632</ArticleId>
            <ArticleId IdType="pubmed">32661059</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kruse C.A., Mitchell D.H., Kleinschmidt-DeMasters B.K., Franklin W.A., Morse H.G., Spector E.B., Lillehei K.O. Characterization of a continuous human glioma cell line DBTRG-05MG: Growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell. Dev. Biol. 1992;28A:609–614. doi: 10.1007/BF02631035.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02631035</ArticleId>
            <ArticleId IdType="pubmed">1331021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ikeda T., Futaesaku Y., Tsuchida N. In vitro differentiation of the human osteosarcoma cell lines, HOS and KHOS. Virchows Arch. B. Cell Pathol. Incl. Mol. Pathol. 1992;62:199–206. doi: 10.1007/BF02899683.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/BF02899683</ArticleId>
            <ArticleId IdType="pubmed">1357821</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mannion N.M., Greenwood S.M., Young R., Cox S., Brindle J., Read D., Nellåker C., Vesely C., Ponting C.P., McLaughlin P.J., et al.  The RNA-Editing Enzyme ADAR1 Controls Innate Immune Responses to RNA. Cell Rep. 2014;9:1482–1494. doi: 10.1016/j.celrep.2014.10.041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.celrep.2014.10.041</ArticleId>
            <ArticleId IdType="pmc">PMC4542304</ArticleId>
            <ArticleId IdType="pubmed">25456137</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robin T., Capes-Davis A., Bairoch A. CLASTR: The Cellosaurus STR similarity search tool—A precious help for cell line authentication. Int. J. Cancer. 2020;146:1299–1306. doi: 10.1002/ijc.32639.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ijc.32639</ArticleId>
            <ArticleId IdType="pubmed">31444973</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dankner M., Rose A.A.N., Rajkumar S., Siegel P.M., Watson I.R. Classifying BRAF alterations in cancer: New rational therapeutic strategies for actionable mutations. Oncogene. 2018;37:3183–3199. doi: 10.1038/s41388-018-0171-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-018-0171-x</ArticleId>
            <ArticleId IdType="pubmed">29540830</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goncharov A.O., Kliuchnikova A.A., Nasaev S.S., Moshkovskii S.A. RNA Editing by ADAR Adenosine Deaminases: From Molecular Plasticity of Neural Proteins to the Mechanisms of Human Cancer. Biochemistry. 2019;84:896–904. doi: 10.1134/S0006297919080054.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1134/S0006297919080054</ArticleId>
            <ArticleId IdType="pubmed">31522671</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rice G.I., Kasher P.R., Forte G.M.A., Mannion N.M., Greenwood S.M., Szynkiewicz M., Dickerson J.E., Bhaskar S.S., Zampini M., Briggs T.A., et al.  Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature. Nat. Genet. 2012;44:1243–1248. doi: 10.1038/ng.2414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/ng.2414</ArticleId>
            <ArticleId IdType="pmc">PMC4154508</ArticleId>
            <ArticleId IdType="pubmed">23001123</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen C.X., Cho D.S., Wang Q., Lai F., Carter K.C., Nishikura K. A third member of the RNA-specific adenosine deaminase gene family, ADAR3, contains both single- and double-stranded RNA binding domains. RNA. 2000;6:755–767. doi: 10.1017/S1355838200000170.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1017/S1355838200000170</ArticleId>
            <ArticleId IdType="pmc">PMC1369955</ArticleId>
            <ArticleId IdType="pubmed">10836796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tan M.H., Li Q., Shanmugam R., Piskol R., Kohler J., Young A.N., Liu K.I., Zhang R., Ramaswami G., Ariyoshi K., et al.  Dynamic landscape and regulation of RNA editing in mammals. Nature. 2017;550:249–254. doi: 10.1038/nature24041.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nature24041</ArticleId>
            <ArticleId IdType="pmc">PMC5723435</ArticleId>
            <ArticleId IdType="pubmed">29022589</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Shanmugam R., Zhang F., Srinivasan H., Charles Richard J.L., Liu K.I., Zhang X., Woo C.W.A., Chua Z.H.M., Buschdorf J.P., Meaney M.J., et al.  SRSF9 selectively represses ADAR2-mediated editing of brain-specific sites in primates. Nucleic Acids Res. 2018;46:7379–7395. doi: 10.1093/nar/gky615.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky615</ArticleId>
            <ArticleId IdType="pmc">PMC6101530</ArticleId>
            <ArticleId IdType="pubmed">29992293</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Roth S.H., Levanon E.Y., Eisenberg E. Genome-wide quantification of ADAR adenosine-to-inosine RNA editing activity. Nat. Methods. 2019;16:1131–1138. doi: 10.1038/s41592-019-0610-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41592-019-0610-9</ArticleId>
            <ArticleId IdType="pubmed">31636457</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vogel C., Marcotte E.M. Insights into the regulation of protein abundance from proteomic and transcriptomic analyses. Nat. Rev. Genet. 2012;13:227–232. doi: 10.1038/nrg3185.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nrg3185</ArticleId>
            <ArticleId IdType="pmc">PMC3654667</ArticleId>
            <ArticleId IdType="pubmed">22411467</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu Y., Beyer A., Aebersold R. On the Dependency of Cellular Protein Levels on mRNA Abundance. Cell. 2016;165:535–550. doi: 10.1016/j.cell.2016.03.014.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cell.2016.03.014</ArticleId>
            <ArticleId IdType="pubmed">27104977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Bathke J., Konzer A., Remes B., McIntosh M., Klug G. Comparative analyses of the variation of the transcriptome and proteome of Rhodobacter sphaeroides throughout growth. BMC Genom. 2019;20:358.  doi: 10.1186/s12864-019-5749-3.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/s12864-019-5749-3</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liberzon A., Birger C., Thorvaldsdóttir H., Ghandi M., Mesirov J.P., Tamayo P. The Molecular Signatures Database Hallmark Gene Set Collection. Cell Syst. 2015;1:417–425. doi: 10.1016/j.cels.2015.12.004.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cels.2015.12.004</ArticleId>
            <ArticleId IdType="pmc">PMC4707969</ArticleId>
            <ArticleId IdType="pubmed">26771021</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kovats S. Estrogen receptors regulate innate immune cells and signaling pathways. Cell. Immunol. 2015;294:63–69. doi: 10.1016/j.cellimm.2015.01.018.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.cellimm.2015.01.018</ArticleId>
            <ArticleId IdType="pmc">PMC4380804</ArticleId>
            <ArticleId IdType="pubmed">25682174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Stelzer G., Rosen N., Plaschkes I., Zimmerman S., Twik M., Fishilevich S., Stein T.I., Nudel R., Lieder I., Mazor Y., et al.  The GeneCards Suite: From Gene Data Mining to Disease Genome Sequence Analyses. Curr. Protoc. Bioinform. 2016;54:1.30.1–1.30.33. doi: 10.1002/cpbi.5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/cpbi.5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lupberger J., Duong F.H.T., Fofana I., Zona L., Xiao F., Thumann C., Durand S.C., Pessaux P., Zeisel M.B., Heim M.H., et al.  Epidermal growth factor receptor signaling impairs the antiviral activity of interferon-alpha. Hepatology. 2013;58:1225–1235. doi: 10.1002/hep.26404.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/hep.26404</ArticleId>
            <ArticleId IdType="pubmed">23519785</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wu S., Zhang Q., Zhang F., Meng F., Liu S., Zhou R., Wu Q., Li X., Shen L., Huang J., et al.  HER2 recruits AKT1 to disrupt STING signalling and suppress antiviral defence and antitumour immunity. Nat. Cell Biol. 2019;21:1027–1040. doi: 10.1038/s41556-019-0352-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0352-z</ArticleId>
            <ArticleId IdType="pubmed">31332347</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gong K., Guo G., Panchani N., Bender M.E., Gerber D.E., Minna J.D., Fattah F., Gao B., Peyton M., Kernstine K., et al.  EGFR inhibition triggers an adaptive response by co-opting antiviral signaling pathways in lung cancer. Nat. Cancer. 2020;1:394–409. doi: 10.1038/s43018-020-0048-0.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-0048-0</ArticleId>
            <ArticleId IdType="pmc">PMC7706867</ArticleId>
            <ArticleId IdType="pubmed">33269343</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Odell I.D., Flavell R.A. HER2 joins AKT to inhibit STING immunity. Nat. Cell Biol. 2019;21:917–918. doi: 10.1038/s41556-019-0368-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41556-019-0368-4</ArticleId>
            <ArticleId IdType="pubmed">31371829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yoshida R., Barbie D.A. EGFR blockade activates interferon. Nat. Cancer. 2020;1:376–378. doi: 10.1038/s43018-020-0055-1.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s43018-020-0055-1</ArticleId>
            <ArticleId IdType="pubmed">35121964</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Athar A., Füllgrabe A., George N., Iqbal H., Huerta L., Ali A., Snow C., Fonseca N.A., Petryszak R., Papatheodorou I., et al.  ArrayExpress update—From bulk to single-cell expression data. Nucleic Acids Res. 2019;47:D711–D715. doi: 10.1093/nar/gky964.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gky964</ArticleId>
            <ArticleId IdType="pmc">PMC6323929</ArticleId>
            <ArticleId IdType="pubmed">30357387</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Branca R.M.M., Orre L.M., Johansson H.J., Granholm V., Huss M., Pérez-Bercoff Å., Forshed J., Käll L., Lehtiö J. HiRIEF LC-MS enables deep proteome coverage and unbiased proteogenomics. Nat. Methods. 2014;11:59–62. doi: 10.1038/nmeth.2732.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nmeth.2732</ArticleId>
            <ArticleId IdType="pubmed">24240322</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barrett T., Wilhite S.E., Ledoux P., Evangelista C., Kim I.F., Tomashevsky M., Marshall K.A., Phillippy K.H., Sherman P.M., Holko M., et al.  NCBI GEO: Archive for functional genomics data sets—Update. Nucleic Acids Res. 2012;41:D991–D995. doi: 10.1093/nar/gks1193.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gks1193</ArticleId>
            <ArticleId IdType="pmc">PMC3531084</ArticleId>
            <ArticleId IdType="pubmed">23193258</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Raoof S., Mulford I.J., Frisco-Cabanos H., Nangia V., Timonina D., Labrot E., Hafeez N., Bilton S.J., Drier Y., Ji F., et al.  Targeting FGFR overcomes EMT-mediated resistance in EGFR mutant non-small cell lung cancer. Oncogene. 2019;38:6399–6413. doi: 10.1038/s41388-019-0887-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/s41388-019-0887-2</ArticleId>
            <ArticleId IdType="pmc">PMC6742540</ArticleId>
            <ArticleId IdType="pubmed">31324888</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jassal B., Matthews L., Viteri G., Gong C., Lorente P., Fabregat A., Sidiropoulos K., Cook J., Gillespie M., Haw R., et al.  The reactome pathway knowledgebase. Nucleic Acids Res. 2020;48:D481–D487. doi: 10.1093/nar/gkz1031.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkz1031</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gene Ontology Consortium  The Gene Ontology resource: Enriching a GOld mine. Nucleic Acids Res. 2021;49:D325–D334. doi: 10.1093/nar/gkaa1113.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/nar/gkaa1113</ArticleId>
            <ArticleId IdType="pmc">PMC7779012</ArticleId>
            <ArticleId IdType="pubmed">33290552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pontén J., Macintyre E.H. Long term culture of normal and neoplastic human glia. Acta Pathol. Microbiol. Scand. 1968;74:465–486. doi: 10.1111/j.1699-0463.1968.tb03502.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1699-0463.1968.tb03502.x</ArticleId>
            <ArticleId IdType="pubmed">4313504</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Reed L.J., Muench H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 1938;27:493–497. doi: 10.1093/oxfordjournals.aje.a118408.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/oxfordjournals.aje.a118408</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dobin A., Davis C.A., Schlesinger F., Drenkow J., Zaleski C., Jha S., Batut P., Chaisson M., Gingeras T.R. STAR: Ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15–21. doi: 10.1093/bioinformatics/bts635.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/bts635</ArticleId>
            <ArticleId IdType="pmc">PMC3530905</ArticleId>
            <ArticleId IdType="pubmed">23104886</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: A Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26:139–140. doi: 10.1093/bioinformatics/btp616.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btp616</ArticleId>
            <ArticleId IdType="pmc">PMC2796818</ArticleId>
            <ArticleId IdType="pubmed">19910308</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>McKenna A., Hanna M., Banks E., Sivachenko A., Cibulskis K., Kernytsky A., Garimella K., Altshuler D., Gabriel S., Daly M., et al.  The Genome Analysis Toolkit: A MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res. 2010;20:1297–1303. doi: 10.1101/gr.107524.110.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1101/gr.107524.110</ArticleId>
            <ArticleId IdType="pmc">PMC2928508</ArticleId>
            <ArticleId IdType="pubmed">20644199</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H., Durbin R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinformatics. 2009;25:1754–1760. doi: 10.1093/bioinformatics/btp324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/bioinformatics/btp324</ArticleId>
            <ArticleId IdType="pmc">PMC2705234</ArticleId>
            <ArticleId IdType="pubmed">19451168</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Broad Institute  Picard.  [(accessed on 1 October 2021)].  Available online:  http://broadinstitute.github.io/picard/</Citation>
        </Reference>
        <Reference>
          <Citation>Levitsky L.I., Ivanov M.V., Lobas A.A., Bubis J.A., Tarasova I.A., Solovyeva E.M., Pridatchenko M.L., Gorshkov M.V. IdentiPy: An Extensible Search Engine for Protein Identification in Shotgun Proteomics. J. Proteome Res. 2018;17:2249–2255. doi: 10.1021/acs.jproteome.7b00640.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jproteome.7b00640</ArticleId>
            <ArticleId IdType="pubmed">29682971</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Teleman J., Chawade A., Sandin M., Levander F., Malmström J. Dinosaur: A Refined Open-Source Peptide MS Feature Detector. J. Proteome Res. 2016;15:2143–2151. doi: 10.1021/acs.jproteome.6b00016.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1021/acs.jproteome.6b00016</ArticleId>
            <ArticleId IdType="pmc">PMC4933939</ArticleId>
            <ArticleId IdType="pubmed">27224449</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang B., Pirmoradian M., Zubarev R., Käll L. Covariation of Peptide Abundances Accurately Reflects Protein Concentration Differences. Mol. Cell. Proteom. 2017;16:936–948. doi: 10.1074/mcp.O117.067728.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1074/mcp.O117.067728</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Vizcaíno J.A., Deutsch E.W., Wang R., Csordas A., Reisinger F., Ríos D., Dianes J.A., Sun Z., Farrah T., Bandeira N., et al.  ProteomeXchange provides globally coordinated proteomics data submission and dissemination. Nat. Biotechnol. 2014;32:223–226. doi: 10.1038/nbt.2839.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1038/nbt.2839</ArticleId>
            <ArticleId IdType="pmc">PMC3986813</ArticleId>
            <ArticleId IdType="pubmed">24727771</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li Y.M., Pan Y., Wei Y., Cheng X., Zhou B.P., Tan M., Zhou X., Xia W., Hortobagyi G.N., Yu D., et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. Cancer Cell. 2004;6:459–469. doi: 10.1016/j.ccr.2004.09.027.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.ccr.2004.09.027</ArticleId>
            <ArticleId IdType="pubmed">15542430</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kwon M., Firestein B.L. DNA transfection: Calcium phosphate method. Methods Mol. Biol. 2013;1018:107–108. doi: 10.1007/978-1-62703-444-9_10.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/978-1-62703-444-9_10</ArticleId>
            <ArticleId IdType="pubmed">23681621</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fukumoto Y., Obata Y., Ishibashi K., Tamura N., Kikuchi I., Aoyama K., Hattori Y., Tsuda K., Nakayama Y., Yamaguchi N. Cost-effective gene transfection by DNA compaction at pH 4.0 using acidified, long shelf-life polyethylenimine. Cytotechnology. 2010;62:73–82. doi: 10.1007/s10616-010-9259-z.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s10616-010-9259-z</ArticleId>
            <ArticleId IdType="pmc">PMC3303003</ArticleId>
            <ArticleId IdType="pubmed">20309632</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
